Want to see SG:9G2 full AI Analyst Report?
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) AI Stock Analysis
Singapore Institute of Advanced Medicine Holdings Ltd.
(SGX:9G2)
The score is held down primarily by weak financial performance—deep losses, negative cash generation, and a material revenue decline—despite positive equity and some improvement in operating cash burn. Technicals are also soft with the stock trading below major moving averages and only neutral momentum signals. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) vs. iShares MSCI Singapore ETF (EWS)
- Market Cap
- SGD 39.65M
- Dividend Yield
- ―
- Average Volume (3M)
- 902.04K
- Price to Earnings (P/E)
- -0.7
- Beta (1Y)
- -0.33
- Revenue Growth
- -1.27%
- EPS Growth
- 16.67%
- Country
- Singapore
- Employees
- 104
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Singapore Institute of Advanced Medicine Holdings Ltd. Business Overview & Revenue Model
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company primarily focused on delivering healthcare services. Its operations include providing pharmaceutical products, surgical supplies, and medical laboratory services. Th...
Singapore Institute of Advanced Medicine Holdings Ltd. Financial Statement Overview
Summary
Overall fundamentals are weak: the company is deeply unprofitable with severely negative net margins (about -152% in 2026) and a sharp revenue decline (~20% YoY in 2026). Cash flow remains negative with ongoing operating cash outflows and negative free cash flow, implying continued funding risk despite some narrowing of operating cash burn in 2026. The balance sheet is not distressed (positive equity) but remains moderately leveraged (debt-to-equity ~1.05–1.16) and returns on equity are strongly negative.
Income Statement
18Very NegativeBalance Sheet
34NegativeCash Flow
22Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.74M | 15.72M | 16.65M | 15.71M | 16.23M | 13.81M |
| Gross Profit | -8.36M | 14.50M | 15.36M | 14.42M | -2.60M | -4.31M |
| EBITDA | -12.37M | -8.97M | -13.42M | -11.08M | -10.60M | -8.02M |
| Net Income | -30.81M | -23.90M | -37.45M | -26.16M | -18.07M | -12.43M |
Balance Sheet | ||||||
| Total Assets | 122.30M | 132.10M | 138.76M | 124.71M | 159.52M | 174.36M |
| Cash, Cash Equivalents and Short-Term Investments | 2.48M | 15.18M | 3.16M | 2.84M | 11.05M | 15.84M |
| Total Debt | 58.62M | 61.28M | 46.10M | 58.21M | 80.77M | 87.30M |
| Total Liabilities | 78.02M | 79.18M | 57.01M | 69.07M | 114.60M | 120.31M |
| Stockholders Equity | 44.28M | 52.92M | 81.74M | 55.64M | 44.93M | 54.05M |
Cash Flow | ||||||
| Free Cash Flow | -5.61M | -4.14M | -14.80M | -10.78M | -19.89M | -11.26M |
| Operating Cash Flow | -5.00M | -3.65M | -14.26M | -10.63M | -5.45M | -7.15M |
| Investing Cash Flow | -166.41K | -67.04K | -263.72K | 113.13K | -1.45M | 3.72M |
| Financing Cash Flow | 2.29M | 15.83M | 6.64M | 10.20M | 2.11M | 9.18M |
Singapore Institute of Advanced Medicine Holdings Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:9G2, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 1.28 is Positive, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:9G2.
Singapore Institute of Advanced Medicine Holdings Ltd. Peers Comparison
Overall Rating
SG:1B172Outperform
SG:BSL66Neutral
SG:A5048Neutral- SG:9G242Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SG:1B1 | 72Outperform | SGD 52.29M | 8.04 | 29.03% | 6.12% | 1.42% | -17.12% |
| SG:BSL | 66Neutral | SGD 1.55B | 22.40 | 6.42% | 3.66% | -3.18% | 6.71% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SG:A50 | 48Neutral | SGD 1.27B | -41.13 | -6.42% | ― | 6.44% | 38.89% |
| SG:9G2 | 42Neutral | SGD 39.65M | -0.72 | -73.80% | ― | -1.27% | 16.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SG:9G2 | Singapore Institute of Advanced Medicine Holdings Ltd. | 0.02 | -0.01 | -28.13% | |
| SG:BSL | Raffles Medical Group | 0.82 | -0.14 | -14.58% | |
| SG:A50 | Thomson Medical Group Ltd. | 0.05 | -0.01 | -20.00% | |
| SG:1B1 | HC Surgical Specialists Ltd | 0.34 | 0.03 | 7.94% | |
| SG:40T | ISEC Healthcare Ltd | 0.31 | -0.02 | -6.91% | |
| SG:5WA | OUE Lippo Healthcare Limited | 0.05 | 0.02 | 68.97% |
Singapore Institute of Advanced Medicine Holdings Ltd. Corporate Events
Singapore Institute of Advanced Medicine revamps board, races to restore committee compliance
Singapore Institute of Advanced Medicine Holdings Ltd. has announced changes to its board and board committees, including the resignation of independent director Gurdip Singh, who also served as chairman of the Audit Committee and member of the Remun...
Singapore Institute of Advanced Medicine Details Use of S$14.94 Million Rights Issue Proceeds
Singapore Institute of Advanced Medicine Holdings Ltd. has detailed how it is deploying net proceeds of about S$14.94 million raised from a renounceable non-underwritten rights cum warrants issue. The capital is being channelled primarily into genera...
Singapore Institute of Advanced Medicine Details Use of S$14.9m Rights Issue Proceeds
Singapore Institute of Advanced Medicine Holdings Ltd. has provided an update on the deployment of approximately S$14.94 million in net proceeds from its renounceable non-underwritten rights cum warrants issue. The company reports that about S$7.13 m...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026